P. Fumoleau

21.4k citations

326 papers · 14.3k indexed · 3 hit papers · h-index 61

Oncology top 0.1%
- Cancer Treatment and Pharmacology 151
- HER2/EGFR in Cancer Research 83
- Colorectal Cancer Treatments and Studies 47
- Neutropenia and Cancer Infections 24
Cancer Research top 0.1%
- Breast Cancer Treatment Studies 79
Dermatology top 0.5%
Radiology, Nuclear Medicine and Imaging top 0.5%
- Monoclonal and Polyclonal Antibodies Research 26
Genetics top 1%
Pulmonary and Respiratory Medicine
- Advanced Breast Cancer Therapies 28
- Lung Cancer Treatments and Mutations 28

Co-authors: Pierre Kerbrat Bruno Coudert Henri Roché Mario Campone Jacques Bonneterre Laurent Arnould Shailendra Verma M. Namer
Cited by: Oncology Cancer Research Dermatology
Journals: Journal of Clinical Oncology (64 papers)European Journal of Cancer (43 papers)Annals of Oncology (32 papers)
Partner nations: France Belgium United States

In The Last Decade

P. Fumoleau

321 papers receiving 13.8k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by P. Fumoleau

Since Specialization

Citations

This map shows the geographic impact of P. Fumoleau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Fumoleau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Fumoleau more than expected).

Fields of papers citing papers by P. Fumoleau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Fumoleau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Fumoleau. The network helps show where P. Fumoleau may publish in the future.

Co-authorship network

The 25 scholars most cited alongside P. Fumoleau, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with P. Fumoleau Line = papers co-authored together P. Fumoleau links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Clinical Cancer Research ·Olivier Humbert,Jean‐Marc Riedinger,Céline Charon‐Barra,Alina Berriolo-Riedinger,Isabelle Desmoulins,Véronique Lorgis,Salim Kanoun,Charles Coutant,P. Fumoleau,Alexandre Cochet,François Brunotte	2015	51
2	Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study European Journal of Cancer ·Xavier Pivot,Thomas Suter,J.-M. Nabholtz,Jean‐Yves Pierga,Marc Espié,Alain Lortholary,David Khayat,Iris Pauporté,Gilles Romieu,Andrew Kramar,P. Fumoleau	2015	49
3	Challenges in the implementation of trastuzumab biosimilars Anti-Cancer Drugs ·Xavier Pivot,G. Aulagner,Jean‐Yves Blay,P. Fumoleau,Alexandre Kaliski,O Ogunsanwo,Samuel Limat	2015	11
4	A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study) The Breast ·P. Fumoleau,Kevin M. Koch,Étienne Brain,François Lokiec,Keyvan Rezaï,Ahmad Awada,Larry Hayward,Gustavo Werutsky,Jan Bogaerts,Sandrine Marréaud,Fátima Cardoso	2014	10
5	Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial Annals of Oncology ·A. Kramar,Thomas Bachelot,Avis Macdonald,Jean‐Yves Pierga,Pierre Kerbrat,Marc Espié,P. Fumoleau,Iris Pauporté,D. Khayat,Gilles Romieu,Xavier Pivot	2014	18
6	6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial The Lancet Oncology ·X. Pivot,Gilles Romieu,Marc Debled,Jean‐Yves Pierga,Pierre Kerbrat,Thomas Bachelot,Alain Lortholary,Marc Espié,P. Fumoleau,Daniel Serin,Jean-Philippe Jacquin,Christelle Jouannaud,María Rios,Sophie Abadie‐Lacourtoisie,N. Tubiana-Mathieu,Laurent Cany,Stéphanie Catala,David Khayat,Iris Pauporté,Andrew Kramar	2013	211
7	Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors Clinical Cancer Research ·Nicolás Isambert,Gilles Freyer,Sylvie Zanetta,Benoît You,P. Fumoleau,Claire Falandry,Laure Favier,Sylvie Assadourian,Karen Soussan-Lazard,SR ANDERSON,V. Trillet-Lenoir	2012	31
8	Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Journal of Clinical Oncology ·Antonio C. Wolff,Ann Lazar,Igor Bondarenko,August Garin,Stephen Brincat,Louis W.C. Chow,Yan Sun,Zora Nešković‐Konstantinović,Rodrigo C. Guimarães,P. Fumoleau,Arlene Chan,元板坂,Andrew Strahs,Maria Cincotta,Anna Berkenblit,Mizue Krygowski,Hery Kristanto,Laurence Moore,Daniel F. Hayes	2012	222
9	Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial The Lancet Oncology ·Paul E. Goss,Ian E. Smith,Joyce O’Shaughnessy,Bent Ejlertsen,Manfred Kaufmann,Frances Boyle,Aman U. Buzdar,P. Fumoleau,William J. Gradishar,Miguel Martín,Beverly Moy,Martine Piccart,Kathleen I. Pritchard,Deborah Lindquist,Yanin Chávarri-Guerra,Gursel Aktan,Erica Rappold,Lisa S. Williams,Dianne M. Finkelstein	2012	100
10	Gene expression profile and response to trastuzumab–docetaxel-based treatment in breast carcinoma British Journal of Cancer ·Frédérique Végran,Romain Boidot,Bruno Coudert,P. Fumoleau,Laurent Arnould,J. L. Garnier,S. Causeret,J Ktiouet,Doulaye Dembélé,Sarab Lizard‐Nacol	2009	25
11	Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study Annals of Oncology ·Patricia Marino,Julius Alsberg,Henri Roché,Christel Protière,P. Fumoleau,M. Spielmann,Anne‐Laure Martin,Patrice Viens,Anne‐Gaëlle Le Corroller	2009	13
12	Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial Annals of Oncology ·Henri Roché,Pierre Kerbrat,Jacques Bonneterre,P. Fargeot,P. Fumoleau,Alain Monnier,P. Clavère,Marie-Josèphe Goudier,P. Chollet,Jean‐Paul Guastalla,D. Serin	2006	48
13	[Role of the combination of trastuzumab and taxanes in the therapeutic management of cancer of the breast: from preclinical data to clinical application]. PubMed ·Mario Campone,Jean‐Louis Merlin,P. Fumoleau	2003	1
14	Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer Annals of Oncology ·G. Ganem,M. Tubiana-Hulin,P. Fumoleau,M. Combe,J. L. Misset,Jean-Michel Vannetzel,Thomas Bachelot,Audra Nareli,Mário Bismarck,Belguendouz Bendahmane,Véronique Dièras	2003	35
15	Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer Annals of Oncology ·Mario Campone,P. Fumoleau,Valérie Delecroix,R. Déporte-Féty,G. Perrocheau,Laurent Vernillet,Isabel S. Pineiro,J.P. Louboutin,Marie-Christine Bissery,A. Riva,N. Azli	2001	20
16	Combined results of 4 phase I and pharmacokinetic (PK) studies of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E UCL Discovery (University College London) ·Alexander Dawe-Coz,P. Fumoleau,Hoffmann-La Roche,憲治野口,Christian Dittrich,C.J.A. Punt,J.P. Droz,AH Calvert,A. van Oosterom,J. Wanders,M. Ravic	2000	7
17	Genetic alterations in early‐onset invasive breast carcinomas: Correlation of c‐erbB‐2 amplification detected by fluorescence In situ hybridization with p53 accumulation and tumor phenotype International Journal of Cancer ·Maryse Fiche,Hervé Avet‐Loiseau,Marie‐Françoise Heymann,Юрий Александрович Ганус,Jan Ivar Botnan,Madeleine Joubert,Jean‐Marc Classe,F. Dravet,P. Fumoleau,Jeffrey S. Ross,Christine M. Maugard	1999	1
18	Genetic alterations in early-onset invasive breast carcinomas: Correlation of c-erbB-2 amplification detected by fluorescenceIn situ hybridization with p53 accumulation and tumor phenotype International Journal of Cancer ·Maryse Fiche,Hervé Avet‐Loiseau,Marie‐Françoise Heymann,Юрий Александрович Ганус,Jan Ivar Botnan,Madeleine Joubert,史裕相田,F. Dravet,P. Fumoleau,Jeffrey S. Ross,Christine M. Maugard	1999	11
19	Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. Journal of Clinical Oncology ·J. L. Misset,Mario Di Palma,Hua Lai,R Plagne,P. Chollet,P. Fumoleau,B. Le Mevel,D Belpomme,J Guerrin,P. Fargeot,R Metz,A. Poli,Catherine Hill,G Mathé	1996	81
20	Phase II Trials of Tetrahydropyranyl-Adriamycin (Pirarubicin) on Renal and Colon Carcinoma, Melanoma, and Soft Tissue Sarcoma American Journal of Clinical Oncology ·H. Roché,Peter Lile,Pierre Kerbrat,Paul Rebattu,P. Fargeot,A Cattan,Jean‐Pierre Armand,R Keiling,M.A. Lentz,V. A. Lesnykh,Patrice Herait,P. Fumoleau	1993	4

About P. Fumoleau

P. Fumoleau is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 326 papers that have together received 14.3k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (151 papers), HER2/EGFR in Cancer Research (83 papers), Breast Cancer Treatment Studies (79 papers), Colorectal Cancer Treatments and Studies (47 papers), Advanced Breast Cancer Therapies (28 papers), Lung Cancer Treatments and Mutations (28 papers), Monoclonal and Polyclonal Antibodies Research (26 papers) and Neutropenia and Cancer Infections (24 papers). The work is most often cited by research in Oncology (9.6k citations), Cancer Research (4.4k citations) and Dermatology (883 citations). P. Fumoleau has collaborated with scholars based in France, Belgium and United States. Frequent co-authors include Pierre Kerbrat, Bruno Coudert, Henri Roché, Mario Campone, Jacques Bonneterre, Laurent Arnould, Shailendra Verma, M. Namer, Véronique Dièras and Pierfranco Conté. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Annals of Oncology, Cancer Chemotherapy and Pharmacology and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact